Clinical Trials Browser

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

NCT03348150 2025-07-17

PERISCOPEII

Phase 3 Active not recruiting

102 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

50 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3 Active not recruiting

381 enrolled 1 FDA

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05623787 2025-03-20

DWI-HighRisk

Phase NA Active not recruiting

30 enrolled

GastrointestinalGynecologic

Appendiceal Neoplasms, Carcinoma, Peritoneal Neoplasms, Colorectal Neoplasms

NCT05185947 2025-03-07

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Phase 2 Active not recruiting

19 enrolled

GastrointestinalGynecologic

Appendiceal Neoplasms, Genital Neoplasms, Female, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT03172416 2024-05-29

PIPAC

Phase 1 Active not recruiting

21 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT04000906 2024-05-24

Nab-PIPAC

Phase 1 Active not recruiting

18 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Peritoneal Neoplasms

NCT02113384 2021-07-28

LARC-EX

Active not recruiting

231 enrolled

GastrointestinalGynecologic

Peritoneal Neoplasms, Rectal Neoplasms

Clinical Trials

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

FLORA-5

CAIRO6

INSIGHT

STOPGAP

KEYLYNK-001

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

PERISCOPEII

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

DWI-HighRisk

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

PIPAC

Nab-PIPAC

LARC-EX